Stockpolly
Search
NXTC · NASDAQ · Biotechnology

NextCure (NXTC)

Developing antibody-drug conjugate candidates for difficult-to-treat cancers.

$7.35
Pre-market−0.05 (−0.68%)
At close$7.40(+8.82%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000100000000
Gross profit000−100000000
16161816121212279101015
Research & development11121112998246777
544344433333
Selling & marketing000−100000000
General & administrative544444433333
Other expenses003000000005
Operating income−16−16−18−16−12−12−12−27−9−10−10−15
111111100000
Other non-operating income0−1−3−1−1−1−100000
Income before tax−14−14−17−15−12−12−11−27−9−9−10−15
Net income from continuing operations−14−14−17−15−12−12−11−27−9−9−10−15
Net income−14−14−17−15−12−12−11−27−9−9−10−15
EPS, basic−$6.16−$6.22−$7.36−$6.61−$4.95−$4.97−$4.70−$11.29−$3.22−$2.69−$1.87−$2.80
EPS, diluted−$6.16−$6.22−$7.36−$6.61−$4.95−$4.97−$4.70−$11.29−$3.22−$2.69−$1.87−$2.80
Weighted average shares, basic222222223455
Weighted average shares, diluted222222223455
EBITDA−15−14−15−15−11−11−10−26−8−9−10−15
Depreciation & amortization111111111000
EBIT−16−14−16−15−12−12−11−27−9−9−10−15